TY - JOUR
T1 - Short article
T2 - Mortality and differential diagnoses of villous atrophy without coeliac antibodies
AU - Schiepatti, Annalisa
AU - Biagi, Federico
AU - Fraternale, Giacomo
AU - Vattiato, Claudia
AU - Balduzzi, Davide
AU - Agazzi, Simona
AU - Alpini, Claudia
AU - Klersy, Catherine
AU - Corazza, Gino R.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Objective: Villous atrophy (VA) of the small bowel is mainly related to coeliac disease (CD), whose diagnosis is made on the basis of positive endomysial/tissue transglutaminase antibodies while on a gluten-containing diet in the vast majority of patients. However, VA can also occur in other conditions whose epidemiology is little known. Our aim was to study the epidemiology and clinical features of these rare enteropathies. Patients and methods: Clinical and laboratory data of all the patients with VA directly diagnosed in our centre in the last 15 years were collected and statistically analysed. Results: Between September 1999 and June 2015, 274 patients were diagnosed with VA. A total of 260 patients were also positive to coeliac antibodies; the other 14 had VA, but no IgA endomysial antibodies: five had common variable immunodeficiency, three had dermatitis herpetiformis, two had IgA deficiency associated with CD, one had abdominal lymphoma, one had unclassified sprue, one had olmesartan-associated enteropathy and one had seronegative CD. Mortality was 6.0 deaths per 100 person years (95% confidence interval: 2.2-16) in patients with VA but negative coeliac antibodies, whereas only 0.2 deaths per 100 person years (95% confidence interval: 0.1-0.6) occurred in coeliac patients. Conclusion: Patients with VA and negative endomysial antibodies are rare. However, these forms of VA identify specific causes that can be diagnosed. These patients are affected by a very high mortality.
AB - Objective: Villous atrophy (VA) of the small bowel is mainly related to coeliac disease (CD), whose diagnosis is made on the basis of positive endomysial/tissue transglutaminase antibodies while on a gluten-containing diet in the vast majority of patients. However, VA can also occur in other conditions whose epidemiology is little known. Our aim was to study the epidemiology and clinical features of these rare enteropathies. Patients and methods: Clinical and laboratory data of all the patients with VA directly diagnosed in our centre in the last 15 years were collected and statistically analysed. Results: Between September 1999 and June 2015, 274 patients were diagnosed with VA. A total of 260 patients were also positive to coeliac antibodies; the other 14 had VA, but no IgA endomysial antibodies: five had common variable immunodeficiency, three had dermatitis herpetiformis, two had IgA deficiency associated with CD, one had abdominal lymphoma, one had unclassified sprue, one had olmesartan-associated enteropathy and one had seronegative CD. Mortality was 6.0 deaths per 100 person years (95% confidence interval: 2.2-16) in patients with VA but negative coeliac antibodies, whereas only 0.2 deaths per 100 person years (95% confidence interval: 0.1-0.6) occurred in coeliac patients. Conclusion: Patients with VA and negative endomysial antibodies are rare. However, these forms of VA identify specific causes that can be diagnosed. These patients are affected by a very high mortality.
KW - coeliac disease
KW - endomysial antibodies
KW - enteropathy
KW - tissue transglutaminase
KW - villous atrophy
UR - http://www.scopus.com/inward/record.url?scp=85009347584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009347584&partnerID=8YFLogxK
U2 - 10.1097/MEG.0000000000000836
DO - 10.1097/MEG.0000000000000836
M3 - Article
C2 - 28350748
AN - SCOPUS:85009347584
SN - 0954-691X
VL - 29
SP - 572
EP - 576
JO - European Journal of Gastroenterology and Hepatology
JF - European Journal of Gastroenterology and Hepatology
IS - 5
ER -